GeneOne Life Science Past Earnings Performance
Past criteria checks 0/6
GeneOne Life Science's earnings have been declining at an average annual rate of -44.2%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been declining at an average rate of 0.6% per year.
Key information
-44.2%
Earnings growth rate
-33.4%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -0.6% |
| Return on equity | -82.3% |
| Net Margin | -191.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
The Market Doesn't Like What It Sees From GeneOne Life Science, Inc.'s (KRX:011000) Revenues Yet As Shares Tumble 39%
Sep 09
Is GeneOne Life Science (KRX:011000) Using Too Much Debt?
Aug 31Why Investors Shouldn't Be Surprised By GeneOne Life Science, Inc.'s (KRX:011000) Low P/S
Jul 26Is GeneOne Life Science (KRX:011000) Using Debt In A Risky Way?
Mar 20GeneOne Life Science (KRX:011000) Has Rewarded Shareholders With An Exceptional 855% Total Return On Their Investment
Jan 10
Revenue & Expenses Breakdown
How GeneOne Life Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 37,969 | -72,691 | 22,711 | 6,115 |
| 30 Jun 24 | 40,802 | -73,645 | 24,406 | 7,076 |
| 31 Mar 24 | 39,841 | -74,037 | 23,999 | 5,501 |
| 31 Dec 23 | 40,203 | -77,768 | 25,782 | 7,043 |
| 30 Sep 23 | 37,294 | -52,617 | 28,982 | 8,554 |
| 30 Jun 23 | 38,116 | -48,964 | 28,397 | 8,743 |
| 31 Mar 23 | 44,176 | -46,740 | 33,518 | 12,132 |
| 31 Dec 22 | 48,718 | -38,150 | 32,279 | 12,147 |
| 30 Sep 22 | 49,074 | -25,772 | 28,613 | 12,736 |
| 30 Jun 22 | 43,041 | -23,369 | 28,300 | 13,458 |
| 31 Mar 22 | 41,443 | -18,680 | 25,778 | 11,685 |
| 31 Dec 21 | 38,700 | -15,888 | 21,702 | 11,441 |
| 30 Sep 21 | 40,498 | -23,160 | 22,786 | 10,377 |
| 30 Jun 21 | 44,780 | -21,007 | 20,987 | 9,761 |
| 31 Mar 21 | 42,305 | -18,355 | 18,909 | 9,217 |
| 31 Dec 20 | 41,503 | -18,648 | 19,547 | 8,396 |
| 30 Sep 20 | 41,938 | -11,890 | 16,779 | 6,873 |
| 30 Jun 20 | 42,539 | -8,939 | 14,988 | 6,448 |
| 31 Mar 20 | 42,244 | -9,282 | 14,833 | 5,454 |
| 31 Dec 19 | 41,241 | -7,619 | 13,500 | 5,874 |
| 30 Sep 19 | 38,578 | -7,725 | 13,556 | 5,938 |
| 30 Jun 19 | 35,856 | -10,233 | 15,588 | 4,380 |
| 31 Mar 19 | 34,037 | -9,344 | 18,150 | 4,507 |
| 31 Dec 18 | 34,293 | -11,898 | 18,441 | 5,661 |
| 30 Sep 18 | 30,802 | -16,198 | 20,720 | 7,454 |
| 30 Jun 18 | 29,802 | -16,872 | 22,028 | 7,454 |
| 31 Mar 18 | 28,147 | -21,727 | 22,311 | 6,815 |
| 31 Dec 17 | 27,171 | -23,730 | 21,141 | 8,398 |
| 30 Sep 17 | 29,849 | -21,068 | 19,706 | 6,787 |
| 30 Jun 17 | 29,449 | -22,167 | 19,492 | 6,787 |
| 31 Mar 17 | 30,785 | -19,401 | 17,473 | 6,757 |
| 31 Dec 16 | 31,371 | -15,599 | 17,043 | 3,931 |
| 30 Sep 16 | 29,013 | -11,435 | 14,438 | 2,567 |
| 30 Jun 16 | 29,151 | -3,227 | 11,505 | 2,567 |
| 31 Mar 16 | 29,409 | 1,031 | 8,899 | 1,826 |
| 31 Dec 15 | 28,365 | 1,414 | 9,206 | 831 |
| 30 Sep 15 | 26,279 | -2,050 | 8,969 | 784 |
| 30 Jun 15 | 24,893 | -6,557 | 8,926 | 784 |
| 31 Mar 15 | 23,652 | -6,977 | 7,864 | 816 |
| 31 Dec 14 | 24,625 | -6,492 | 8,141 | 759 |
| 30 Sep 14 | 27,367 | -3,179 | 7,356 | 2,569 |
| 30 Jun 14 | 25,343 | -3,993 | 6,997 | 2,569 |
| 31 Mar 14 | 23,671 | -5,473 | 6,974 | 2,420 |
| 31 Dec 13 | 20,657 | -8,363 | 6,446 | 2,392 |
Quality Earnings: A011000 is currently unprofitable.
Growing Profit Margin: A011000 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A011000 is unprofitable, and losses have increased over the past 5 years at a rate of 44.2% per year.
Accelerating Growth: Unable to compare A011000's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A011000 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.8%).
Return on Equity
High ROE: A011000 has a negative Return on Equity (-82.34%), as it is currently unprofitable.